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Introdução:O envelhecimento é um processo complexo que influencia todos os sistemas do corpo humano e seu impacto no sistema 
imune é chamado Imunosenescência. Essa condição é resultado de várias modulações imunológicas causadas por interações entre 
fatores genéticos e ambientais e é responsável por importantes condições clínicas em indivíduos idosos como alta prevalência de 
doenças infecciosas e autoimunes, neoplasias e menor eficácia de vacinas. Objetivo: Nesta revisão serão discutidos os problemas 
clínicos mais comuns na população idosa relacionados a Imunosenescência, e os novos achados da ciência básica relevantes a este 
tópico. Conclusão: A melhor compreensão da Imunosenescência é importante para prevenção de doenças comuns relacionadas à 
idade e para a promoção de um envelhecimento saudável.  





Background: Ageing is a very complex process that modulates all the organ systems of the human body, and its impact on the 
immune system is called Immunosenescence. This condition is the result of several immune modulations due to genetic and 
environmental interactions and is responsible for important clinical conditions in elderly subjects, such as a higher incidence of 
infectious and autoimmune diseases, neoplasias and decreased vaccine efficacy. Objective: In this current review we will discuss the 
most common clinical problems in the elderly population related to Immunosenescence and new findings in basic science relevant to 
this topic. Conclusion: A better understanding of Imunosenescence is important to prevention of common age related diseases and 
for the promotion of healthy ageing.   
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INTRODUCTION  
 
One way to measure the quality and 
success of a society is the life expectancy or in 
other words, life and health span. The recent 
social, economic and technological 
development is causing a fast ageing of the 
world population, especially in developed 
countries. Brazil being a developing country, is 
facing a rapid increase of its elderly population. 
Currently, 11% of the Brazilian population is 
composed of subjects older than 60 1. This 
demographical transition implies a great 
change in social structures, such as the health 
care system. The elderly population demands a 
different and specialized care with focus on 
treatment of chronic and degenerative 
diseases, prevention of disability, frailty and 
infectious diseases.  
From a biological point of view, ageing 
is a very complex process that modulates all the 
organ systems of the human body, and its 
impact on the immune system is called 
Immunosenescence. Franceschi et.al2. 
proposed a simple equation to better 
understand the interaction between ageing and 
the immune system : Stress resistance = Ability 
to survive. Adopting an evolutionary point of 
view, the capacity to deal with environmental 
and physiological challenges prolongs 
survivability and as a result expose organisms 
once more to new stressors, promoting an 
endless selection process. In other words, the 
evolution of the immune system resulted in 
lifespan extension and ageing in its own way 
modulates the defense mechanisms based on 
the new environment and physiologic 
demands. The human innate and adaptive 
immune responses thus pass through several 
changes dictate by different challenges during 
ageing.  
The immune system ageing is 
characterized by a decrease of hematopoietic 
stem cells and thymus involution, leading to a 
decline in the replenishment of naïve T and B 
cells. Interaction with environmental triggers 
leads to a shift from naïve to memory cells, an 
expansion of oligoclonal memory cells related 
to cytomegalovirus (CMV), and a low grade and 
persistent inflammatory state2-5. The ageing 
phenotype is a result of the sum of all these 
immune modulations and has been correlated 
with several clinical conditions such as 
increased incidence of inflammatory, 
neurodegenerative and infectious diseases, 
frailty, decreased vaccine efficacy and 
occurrence of some age-related neoplasms6-11. 
In this current review we will discuss 
the most common clinical problems in the 
elderly population related to 
Immunosenescence and new findings in basic 






Is there a maker of immune ageing? - The 
immune risk profile.  
 
Humans have always pursued the 
secret of longevity. Despite intense 
investigation, only recently some studies 
identified certain immune characteristics able 
to predict mortality in elderly populations. The 
sum of these immune factors is called “Immune 
Risk Profile” (IRP), and were identified for the 
first time in the large Swedish OCTO/NONA12,13 
cohort study. It was observed that elderly 
subjects with a CD4/CD8 ratio < 1, CMV IgG 
serum positivity, and expansion of CD8+ CD28- 
cell population exhibited higher mortality 
irrespective of health status. An extension of 
this study has found that CD4/CD8 ratio <1 was 
in fact the best independent predictor of 
mortality and ratios >1  were correlated with 
successful ageing14,15. Despite the robust 
evidence, further studies did not confirm the 
same IRP variables in different elderly 
populations around the world, suggesting that 
immune ageing can be a heterogeneous 
process.    
An interesting note covered in the 
original IRP was the identification of a viral 
infection playing a role in the ageing process. 
Further studies documented a close 
relationship between CMV chronic infection 
and modulations of T cell subsets. The CMV IgG 
serum positivity has been correlated with 
accumulation of highly differentiated effector T 
cells16. This cell subset is characterized by an 
impaired capacity to migrate to lymph nodes, 
decreased ability to being stimulated by APC 
and higher production of pro inflammatory 
cytokines.  
In summary, there is not a robust 
marker of immune ageing. The decline of CD8 
naïve T cells and the occurrence of CD28- T cells 
are the most common and reproducible 
findings in different elderly populations, but its 
impact in healthy ageing and disease 
development is not clear yet. 
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Sometimes more is less. - Inflammageing a 
silent killer.  
 
The inflammatory response is the 
crucial physiological response to the constant 
immunological challenges that we are exposed 
to in daily life. Several studies have observed a 
progressive low-grade inflammation that 
follows the ageing process termed 
Inflammageing. Inflammageing has been 
characterized as an unbalance between pro and 
anti-inflammatory factors resulting in increased 
serum levels of IL-6, TNF-α and acute phase 
proteins such as CRP2. This condition has been 
correlated with the development of important 
clinical conditions such as frailty, cancer and 
cardiovascular diseases 17-19. Although several 
transversal studies correlated CMV infection 
with Inflammageing, a recent longitudinal study 
did not find any association between this viral 
infection and an increase of inflammatory 
cytokines20. 
 In healthy centenarians it has 
been observed that higher production of anti-
inflammatory factors is protective and 
contributes to longer survival. Lio et.al21.found 
that healthy centenarians have higher serum 
levels of TGF- β and carry a higher frequency of 
an IL-10 gene polymorphism that promotes 
higher IL-10 production when compared to 
controls. The Leiden 85+ cohort study22 also 
revealed that individuals with higher IL-10 
serum levels presented lower cardiovascular 
mortality when compared with subjects with 
lower levels of IL-10.   
The Groningen Research Initiative on 
Healthy Ageing and Immune Longevity (GRAIL) 
group is conducting several research projects 
related to Inflammageing. Based on the 
evidence that B cells can present pro and anti-
inflammatory roles through their cytokine 
production profile, our group explored the 
impact of ageing on cytokine producing B cells. 
The population of effector B cells is 
characterized by production of TNF-α and IL-6, 
promoting inflammation, and disturbances in 
this subset have been reported in diseases such 
as rheumatoid arthritis, giant cell arteritis and 
polymyalgia rheumatica23,24. On the other hand, 
B cells can block the inflammatory response 
inhibiting TNF-α and IFN-γ production by T cells 
in an IL-10 dependent way. IL-10 producing B 
cells are termed  B regulatory cells (Breg). 
Decreased numbers of Breg have been 
correlated with several inflammatory diseases 
such as systemic lupus erythematous, multiple 
sclerosis and rheumatoid arthtritis25-27. In a 
cross sectional study we have found that 
regulatory B cells numbers tends to decrease 
with ageing whereas we did not find any 
modulation of the effector B cell subset. Thus, 
ratio’s of Beff/Breg increase with ageing 
thereby favoring pro-inflammation. Our 
findings suggest a new players in 
Inflammageing: the B effectors and the Bregs 
(unpublished data). 
  
Preventing severe complications of common 
diseases -Vaccination response in elderly. 
 
Vaccination should be regarded as a 
milestone in the quest for extension of life 
expectancy for mankind, making prevention of 
several life threatening infectious diseases 
possible. A particular health issue is the 
vaccination of the elderly population since 
infectious diseases incidence increases with 
age6. Several clinical and epidemiological 
studies have shown a decreased vaccine 
response in older subjects. Both the innate and 
the adaptive immune system are involved in 
this process. The aged innate response displays 
diminished migration and phagocytic activity of 
neutrophils and macrophages summed to 
decreased numbers of APC cells and reduced 
expression of MHC I and II as well28,29. On the 
other hand, the aged adaptive response is 
impaired due to decreased numbers of naïve T 
and B cells, accumulation of highly 
differentiated effector T cells, decreased 
expression of CD40-ligand by CD4+ cells, defects 
in isotype switching and somatic mutation in B 
cells30-35. This highly disturbed immune 
response contributes to increased susceptibility 
to infectious diseases and is a challenge to be 
overtaken by the development of new vaccines.  
 
Changing old for new – The challenge 
of transplantation medicine in elderly subjects. 
 
The improvement of chronic diseases 
care is leading to an increase in the prevalence 
of end stage organ failures. Since regenerative 
medicine and stem cells therapy are not 
feasible treatments yet, organ transplantation 
is the best alternative for these conditions. Age 
is one of the most important factors in 
transplant outcome and Immunosenescence 
plays an important role in this clinical scenario. 
Several epidemiological studies have reported 
lower incidences of acute graft rejection in 
elderly recipients36-38, however the mortality 
and chronic rejection are still higher in this 
population39,40. Most of the authors attributes 
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this different clinical outcome to the same 
immune changes that also determine/impact 
the impaired vaccine response.  
 
Autoimmune diseases: Age marked pathologies. 
 
The correlation between 
Immunosenescence and autoimmune diseases 
is based on several epidemiological and 
laboratory data. It is important to note that 
autoimmune disorders are more prevalent in 
older subjects particularly with rheumatoid 
arthritis, giant cell arteritis and polymyalgia 
rheumatica6. This fact can be explained by a 
breach of tolerance that follows ageing. The 
low naïve T cell output due to thymus 
involution may induce an intense proliferation 
of peripheral naïve T cells, resulting in impaired 
selection and replication of naïve and memory 
self-reactive T cells. Insufficiency of telomerase 
activity, deficiency of DNA repair mechanisms 
and accumulation of CD28- cells may also 
contribute to the pathogenesis, promoting 
inflammation and impaired regulatory 
capacity41-43. Noteworthy, several of these 
characteristics can be observed in RA patients, 
despite disease duration and treatment, 
suggesting that these subjects present with a 





Immunosenescence is a complex 
phenomenon that affects all the components of 
the immune system and depends on genetic 
and environmental factors. Accumulation of 
oligoclonal highly differentiated T cells and 
increasing serum levels of pro inflammatory 
cytokines might be main events responsible for 
the immune impairment in elderly subjects. 
Healthy centenarians provide living proof that 
effective immune responses can be maintained 
for decades, even after thymus involution. 
More immunogerontology studies are required 
to understand immune competence and 
immune dysfunction with ageing. A better 
understanding may hold promise for future 
clinical studies for the prevention of common 
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